RadNet buys Gleamer for up to €230M to become the world's top radiology AI provider
What's the deal? RadNetDealroom has a profile for this one. Try Dealroom →, a US outpatient imaging giant, has acquired Gleamer, a Paris-based radiology AI firm, for up to €230 million in an all-cash deal. The acquisition folds Gleamer into DeepHealth, RadNet's AI subsidiary, making it the largest provider of radiology clinical AI solutions worldwide.
Gleamer, founded in 2017, serves over 700 customer contracts across 44 countries. Its cloud-first platform covers X-ray, mammography, CT, and MRI, with solutions cleared by both the FDA and CE-marked for Europe.
Why now? Imaging volumes are rising globally while radiologist shortages are worsening — a pressure cooker that makes AI-driven workflow automation urgent. Gleamer's annual recurring revenue (ARR) grew at a compound rate exceeding 90% between 2022 and 2025, and it is on track to hit roughly $30 million ARR in 2026.
The timing also suits RadNet's own momentum. It just reported record revenue of $547.7 million in Q4 2025, up nearly 15% year on year — giving it the financial firepower to move.
What could go wrong? Integration is rarely smooth. Merging a fast-moving, cloud-native French startup into a large US healthcare operator brings cultural, technical, and regulatory complexity. RadNet is betting that Gleamer's automated reporting tools, already deployed in Europe, can be rolled out across its US imaging network by Q3 2026 — an ambitious timeline.
The combined entity will also need to prove it can hold its ground against deep-pocketed rivals in a crowded radiology AI market.
The signal: The deal reflects a broader consolidation wave in medical AI, as established healthcare operators move to own the software layer rather than just buy access to it. With a combined installed base of over 2,700 customer contracts in 50+ countries and a target of approaching or exceeding $140 million ARR by end of 2026, DeepHealth is positioning itself as the default AI infrastructure for radiology worldwide.
The message to the market is clear: scale and breadth of clinical coverage — across modalities, geographies, and indications — are becoming the decisive competitive moat.
Sources:
DeepHealth
Radnet
Radnet
GlobeNewswire
MassDevice
Radiology Business
StreetInsider
Image credit:
Gleamer
J.V.
